{"id":"NCT02322593","sponsor":"Taiho Pharmaceutical Co., Ltd.","briefTitle":"Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer","officialTitle":"An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2019-02","completion":"2020-05","firstPosted":"2014-12-23","resultsPosted":"2021-12-20","lastUpdate":"2021-12-20"},"enrollment":711,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer"],"interventions":[{"type":"DRUG","name":"TAS-118 plus Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"S-1 plus Cisplatin","otherNames":[]}],"arms":[{"label":"TAS-118/Oxaliplatin","type":"EXPERIMENTAL"},{"label":"S-1/Cisplatin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"A survival follow-up was required every 12 weeks from the date of randomization to the date of death from any cause, whichever came first, assessed up to 38 months.","effectByArm":[{"arm":"TAS-118/Oxaliplatin","deltaMin":16,"sd":null},{"arm":"S-1/Cisplatin","deltaMin":15.1,"sd":null}],"pValues":[{"comp":"OG000","p":"0.039"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":6,"countries":["Japan","South Korea"]},"refs":{"pmids":["32682457"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":155,"n":352},"commonTop":["Decreased appetite","Nausea","Diarrhoea","Peripheral sensory neuropathy","Stomatitis"]}}